Download PDF
Thromb Haemost 1995; 74(06): 1442-1446
DOI: 10.1055/s-0038-1649962
Original Articles
Clinical Studies
Schattauer GmbH Stuttgart

Blood Coagulation and Fibrinolysis Activation during Sudden Arterial Occlusion of Lower Extremities – an Association with Ischemia and Patient Outcome

Seija Peltonen
1   The Wihuri Research Institute, Helsinki, Finland
,
Riitta Lassila
1   The Wihuri Research Institute, Helsinki, Finland
,
Perttu Rossi
2   The Department of Surgery, Tampere University Hospital, Tampere, Helsinki, Finland
,
Juha-Pekka Salenius
2   The Department of Surgery, Tampere University Hospital, Tampere, Helsinki, Finland
,
Mauri Lepäntalo
3   The Department of Surgery, Division of Vascular Surgery, Helsinki University Central Hospital, Helsinki, Finland
› Author Affiliations
Further Information

Publication History

Received: 05 July 1995

Accepted after revision 28 August 1995

Publication Date:
10 July 2018 (online)

  PDF Download  Permissions and Reprints

Summary

We compared hemostatic and fibrinolytic plasma markers in 41 patients having acute or subacute occlusion of lower limb arteries with 20 patients suffering stable peripheral arterial occlusive disease (PAOD). During occlusion, the amount of thrombin-antithrombin III (TAT) complex was five-fold higher compared with stable PAOD, being 16 μg/l [95% confidence interval (CI) 11-21 μg/1] vs 3 μg/l (95% CI 2-4 μg/l), p <0.003. Similarly, D-dimer was over four-fold (p = 0.0001), while tissue plasminogen activator and plasminogen activator inhibitor-1 (PAI-1) antigens were about two-fold (p = 0.02 and p <0.003, respectively) higher than in PAOD. Coagulation and fibrinolysis markers were increased most in patients with recent symptom onset, which mainly represented embolus rather than thrombosis. The marker levels assessing coagulation and fibrinolysis were related with myoglobin and CK, indicators of skeletal muscle damage. Finally, increased TAT, PAI-1 antigen, and myoglobin concentrations associated with poor outcome.

 

  • References

  • 1 Teitel JM, Bauer KA, Lau HK, Rosenberg RD. Studies of the prothrombin activation pathway utilizing radioimmunoassay for the F2/F1+2 fragment and the thrombin-antithrombin complex. Blood 1982; 59: 1086-1097
    PubMedGoogle Scholar
  • 2 Pelzer H, Schwarz A, Heimburger N. Determination of human thrombin antithrombin III complex in plasma with an enzyme-linked immunosorbent assay. Thromb Haemost 1988; 59: 101-106
    Article in Thieme ConnectPubMedGoogle Scholar
  • 3 Pelzer H, Schwart A, Stuber W. Determination of human prothrombin activation fragment 1+2 in plasma with an antibody against the synthetic peptide. Thromb Haemost 1991; 65: 153-159
    Article in Thieme ConnectPubMedGoogle Scholar
  • 4 Nieuwenhuizen W. Plasma assays for derivatives of fibrin and fibrinogen, based on monoclonal antibodies. Fibrinolysis 1988; 2: 1-5
    PubMedGoogle Scholar
  • 5 Bounameaux H, Cirafici P, de Moerloose P, Schneided PA, Slossman D, Reber G, Unger PF. Measurement of D-dimer in plasma as diagnostic aid in suspected pulmonary embolism. Lancet 1990; 337: 196-200
    PubMedGoogle Scholar
  • 6 Boneu B, Bes G, Pelzer H, Sie P, Boccalon H. D-dimers, thrombin-antithrombin III complexes and prothrombin fragments 1+2 diagnostic value in clinically suspected deep vein thrombosis. Thromb Haemost 1991; 65: 28-32
    Article in Thieme ConnectPubMedGoogle Scholar
  • 7 Szczeklik A, Dropinski J, Radwan J, Krzanowski M. Persistent generation of thrombin after acute myocardial infarction. Arteriosclerosis Thrombosis 1992; 12: 548-553
    CrossrefPubMedGoogle Scholar
  • 8 Merlini PA, Bauer KA, Oltrona L, Adrissino D, Cattaneo M, Belli C, Mannucci M. Persistent activation of the coagulation mechanism in unstable angina and myocardial infarction. Circulation 1994; 90: 61-68
    CrossrefPubMedGoogle Scholar
  • 9 Lassila R, Peltonen S, Lepäntalo M, Saarinen O, Kauhanen P, Manninen V. Severity of peripheral atherosclerosis is associated with fibrinogen and degradation of cross-linked fibrin. Arterioscler Thromb 1993; 13: 1738-1742
    CrossrefPubMedGoogle Scholar
  • 10 Herren T, Strecker H, Haeberli A, Do D-D, Straub PW. Fibrin formation and degradation in patients with arteriosclerotic disease. Circulation 1994; 90: 2679-2686
    CrossrefPubMedGoogle Scholar
  • 11 Heinrich J, Schulte H, Schönfeld R, Köhler E, Assman G. Association of variables of coagulation, fibrinolysis and acute-phase with atherosclerosis in coronary and peripheral arteries and those arteries supplying the brain. Thromb Haemost 1995; 73: 374-379
    Article in Thieme ConnectPubMedGoogle Scholar
  • 12 Fowkes FG R, Lowe GD O, Housley E, Rattray A, Rumley A, Elton RA, MacGregor IR, Dawes J. Cross-linked fibrin degradation products, progression of peripheral arterial disease, and risk of coronary heart disease. Lancet 1993; 342: 84-86
    CrossrefPubMedGoogle Scholar
  • 13 Cortellaro M, Cofrancesco E, Boschetti C, Mussoni L, Donati MB, Cardillo M, Catalano M, Garbrielli L, Lombardi B, Specchia G, Tavazzi L, Tremoli E, Pozzoli E, Turri M. Increased fibrin turnover and high PAI-1 activity as predictors of ischemic events in atherosclerotic patients. A case- control study Arterioscler Thromb 1993; 13: 1412-1417
    CrossrefPubMedGoogle Scholar
  • 14 Rutherford RB, Flanigan DP, Gupta SK, Johnston KW, Karmody A, Whittemore AD, Baker JD, Ernst CB. Suggested standards for reports dealing with lower extremity ischemia. J Vase Surg 1986; 4: 80-94
    CrossrefPubMedGoogle Scholar
  • 15 Takolander R. Differentation between acute and acute on chronic limb ischaemia. Ann Chir Gynaecol 1992; 81 (02) 143-145
    PubMedGoogle Scholar
  • 16 Kluft C, Verheijen JH. Leiden fibrinolysis working party: blood collection and handling procedures for assessment of tissue-type plasminogen activator (t-PA) and plasminogen activator inhibitor-1 (PAI-1). Fibrinolysis 1990; 4 suppl (Suppl. 02) 155-161
    PubMedGoogle Scholar
  • 17 European Committee for Clinical Laboratory Standards. Standards for Enzyme Determination. Determination of the catalytic activity concentration in serum of creatine kinase (EC2.7.3.2., CK) Klin Lab 1990; 6: 120-126
    PubMedGoogle Scholar
  • 18 Rosano TG, Kenny MA. A radioimmunoassay for human serum myoglobin: method, development and normal values. Clin Chem 1977; 23: 69-75
    PubMedGoogle Scholar
  • 19 Campbell MJ, Machin D. Medical statistics. John Wiley & Sons Ltd; Chichester, England: 1992. pp 80-81
    Google Scholar
  • 20 Kumagai K, Fukunami M, Ohmori M, Kitabatake A, Takenobu K, Hoki N. Increased intracardiovascular clotting in patients with chronic atrial fibrillation. J Amer Coll Cardiol 1990; 16: 377-380
    CrossrefPubMedGoogle Scholar
  • 21 Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med 1992; 326: 242-250
    CrossrefPubMedGoogle Scholar
  • 22 Ljungman C, Eriksson I, Ronquist G, Roxin LE, Venge P, Wistrand P. Muscle ATP and lactate and the release of myoglobin and carbanhydrase III in acute lower-limb ischaemia. Eur J Vase Surg 1991; 5: 407-414
    CrossrefPubMedGoogle Scholar
  • 23 Bauer KA. New markers for in vivo coagulation. Curr Opin Hematol 1994; 1: 341-346
    PubMedGoogle Scholar
  • 24 Diquelou A, Lemozy S, Dupouy B, Boneu B, Sakariassen KS, Cadroy Y. Effect of blood flow on thrombin generation is dependent on the nature of the thrombogenic surface. Blood 1994; 84: 2206-2213
    PubMedGoogle Scholar
  • 25 Jackson GM. Mechanisms of prothrombin activation. In: Hemostasis and Thrombosis. Basic Principles and Clinical Practice. Colman RW, Hirsh J, Marder VJ, Salzman EW. eds. J.B. Lippincott Company; Philadelphia, PA: 1987. pp 135-147
    Google Scholar
  • 26 Fenton II JW, Ofosu FA, Brezniak DV, Hassouna HI. Understanding thrombin and hemostasis. Hematol/Oncol Clin N Am 1994; 7: 1107-1119
    PubMedGoogle Scholar
  • 27 Smith FB, Lee AJ, Rumley A, Fowkes GR, Lowe GD O. Tissue-plasminogen activator, plasminogen activator inhibitor and risk of peripheral arterial disease. Atherosclerosis 1995; 115: 35-43
    CrossrefPubMedGoogle Scholar
  • 28 Stringer HA R, van Swieten P, Heijnen HF G, Sixma JJ, Pannekoek H. Plasminogen activator inhibitor-1 released from activated platelets plays a key role in thrombolysis resistance: studies with thrombi generated in the Chandler loop. Arterioscler Thromb 1994; 14: 1452-1458
    CrossrefPubMedGoogle Scholar